Dolutegravir: An exciting new kid on the block

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 4, 2014, Pages 573-582

  Blanco Arévalo, Jose Luis ^a   Whitlock, Gary George ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

Antirtroviral therapy; Dolutegravir; HIV; Integrase inhibitors

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; CREATININE; DOLUTEGRAVIR; INTEGRASE; INTEGRASE INHIBITOR; VIRUS ENZYME;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ARTICLE; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME STRUCTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERBILIRUBINEMIA; IN VITRO STUDY; INSOMNIA; NAUSEA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; RHINOPHARYNGITIS;

CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG RESISTANCE, VIRAL; GENETIC THERAPY; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HUMANS; MUTATION; PROTEIN CONFORMATION;

EID: 84893668867     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.868883     Document Type: Article

References (39)

1. Espeseth AS, Felock P, Wolfe A, et al. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc Natl Acad Sci USA 2000;97:11244-9
2. Hare S, Gupta SS, Valkov E, et al. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010;464:232-6
3. Alian A, Griner SL, Chiang V, et al. Catalytically-Active complex of HIV-1 integrase with a viral DNA substrate binds anti-integrase drugs. Proc Natl Acad Sci USA 2009;106:8192-7
4. McColl DJ, Chen X. Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. Antiviral Res 2010;85:101-18
5. Mouscadet JF, Delelis O, Marcelin AG, Tchertanov L. Resistance to HIV-1 integrase inhibitors: a structural perspective. Drug Resist Updat 2010;13:139-50
6. Metifiot M, Marchand C, Maddali K, Pommier Y. Resistance to integrase inhibitors. Viruses 2010;2:1347-66
7. Min S, Song I, Borland J, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor in healthy volunteers. Antimicrob Agents Chemother 2010;54:254-8
8. Cottrell M, Hadzic T, Kashuba A. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet 2013;52:981-94
9. Min S, Sloan L, DeJesus E, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS 2011;25:1737-45
10. Song I, Borland J, Shuguang C, et al. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother 2012;56(3):1627-9
11. Song I, Min SS, Borland J, et al. Lack of interaction between the HIV integrase inhibitor S/GSK1349572 and tenofovir in healthy subjects. J Acquir Immune Defic Syndr 2010;55:365-7
12. Song I, Borland J, Min S, et al. Effects of etravirine alone and with ritonavirboosted protease inhibitors on the pharmacokinetics of dolutegravir. Antimicrob Agents Chemother 2011;55:3517-21
13. Song I, Mark S, Borland J, et al. Dolutegravir has no effect on the pharmacokinetics of methadone or oral contraceptives with norgestimate and ethinyl estradiol [abstract 535]. 20th Conference on Retroviruses and Opportunistic Infections; 3 -6 March 2013; Atlanta
14. Patel P, Song I, Borland J, et al. Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-Administered with acid-reducing agents and multivitamins in healthy volunteers. J Antimicrob Chemother 2011;66:1567-72
15. Stellbrink H-J, Reynes J, Lazzarin A, et al. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS 2013;27:1771-8
16. Walmsley S, Antela A, Clumeck N, et al. Dolutegravir (DTG; S/GSK1349572) + abacavir/lamivudine once daily statistically superior to tenofovir/ emtricitabine/efavirenz: 48-week results -SINGLE (ING114467) [abstract H556b]. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 9 -12 September 2012; San Francisco
17. Raffi F, Rachlis A, Stellbrink H-J, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-na?ve adults with HIV-1 infection: 48 week results from the randomized, double-blind, non-inferiority SPRING-2 study. Lancet 2013;381:735-43
18. Feinberg J Clotet B, Khuong MA, et al. Once-daily dolutegravir is superior to darunavir/ritonavir in antiretroviral na?ve adults: 48 week results from FLAMINGO (ING114915) [abstract H-1464a]. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 10 -13 September 2013; Denver
19. Clotet B, Khuong MA, Antinori A, et al. Once-daily dolutegravir versus darunavir/ritonavir in antiretroviral naive adults: 48 week subgroup analyses from FLAMINGO [abstract LBPS4/6]. Program and abstracts of the 14th European AIDS Conference; 16 -19 October 2013; Brussels, Belgium
20. Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 2013;282(9893):700-8
21. Sato A, Seki T, Kobayashi M, et al. In vitro passage of drug resistant HIV-1 against a next generation integrase inhibitor (INI), S/GSK1349572 [abstract H-932]. 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting; 12 -15 September 2009; San Francisco, CA
22. Seki T, Kobayashi M, Wakasa-Morimoto C, et al. S/GSK1349572 is a potent next generation HIV integrase inhibitor and demonstrates a superior resistance profile substantiated with 60 integrase mutant molecular clones [abstract 555]. 17th Conference on Retroviruses and Opportunistic Infections; 16 -19 February 2010; San Francisco, CA
23. Eron JJ, Clotet B, Durant J, et al. Safety and efficacy of dolutegravir in treatmentexperienced subjects with raltegravirresistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis 2013;207:740-8
24. Nichols G, Lazzarin A, Maggiolo F, et al. Phase 3 assessment of dolutegravir (DTG) 50 mg twice daily in HIV-1-infected subjects with raltegravir (RAL) and/or elvitegravir (EVG) resistance in VIKING-3: week 24 results of all 183 patients enrolled [abstract TULBPE19]. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; June 30-July 3 2013; Kuala Lumpur
25. Curtis L, Min S, Nichols G, et al. Once-daily dolutegravir (DTG; S/GSK1349572) has a renal safety profile comparable to raltegravir (RAL) and efavirenz in antiretroviral (ART)-na?ve adults: 48 week results from SPRING-2 (ING113086) and SINGLE (ING114467) [abstract TUPE282]. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; June 30 -July 3 2013; Kuala Lumpur
26. Fransen S, Young B, Frantzell A, et al. Control of viral replication following transmission of HIV-1 exhibiting resistance to reverse transcriptase, protease, and integrase inhibitors [abstract 56]. Antiviral Ther 2010;15(Suppl 2):A67
27. Varghese V, Liu TF, Rhee SY, et al. HIV-1 integrase sequence variability in antiretroviral na?ve patients and in tripleclass experienced patients subsequently treated with raltegravir. AIDS Res Hum Retroviruses 2010;26:1323-6
28. Gutierrez C, Hernandez-Novoa B, Perez-El?as MJ, et al. Prevalence of primary resistance mutations to integrase inhibitors in treatment-na?ve and -experienced patients infected with B and non-B HIV-1 variants. HIV Clin Trials 2013;14(1):10-16
29. Ceccherini-Silberstein F, Malet I, DArrigo R, et al. Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev 2009;11:17-29
30. Vavro C, Hasan S, Madsen H, et al. Prevalent polymorphisms in wild-type HIV-1 integrase are unlikely to engender drug resistance to dolutegravir (S/GSK1349572). Antimicrob Agents Chemother 2013;57:1379-84
31. Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 2011;55:813-21
32. Quashie PK, Mesplede T, Han YS, et al. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 2012;86:2696-705
33. Underwood MR, Dudas K, Horton J, et al. Analysis and characterization of treatment-emergent resistance in ART-experienced, integrase inhibitornaive subjects with dolutegravir (DTG) vs raltegravir (RAL) in SAILING (ING111762) [abstract 21]. International Workshop on HIV &hepatitis virus drug resistance and curative strategies; 4 -8 June 2013; Toronto, ON, Canada
34. Quinones-Mateu ME, Moore-Dudley DM, Jegede O, et al. Viral drug resistance and fitness. Adv Pharmacol 2008;56:257-96
35. Mesplede T, Quashie PK, Osman N, et al. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology 2013;10:22
36. Vavro CL, Huang J, Underwood MR, et al. Integrase genotypic and phenotypic predictors of antiviral response to dolutegravir (DTG) in subjects with resistance to integrase inhibitors (INIs) [abstract 29]. International Workshop on HIV & hepatitis virus drug resistance and curative strategies; 4 -8 June 2013; Toronto, ON, Canada
37. Hightower KE, Wang R, Deanda F, et al. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother 2011;55:4552-9
38. Canducci F, Ceresola ER, Boeri E, et al. Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. J Infect Dis 2011;204:1811-15
39. Abram ME, Hluhanich RM, Goodman DD, et al. Impact of primary elvitegravir resistance-Associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antimicrob Agents Chemother 2013;57:2654-63